Dr. Soff discusses results from a phase II study of romiplostim in treating patients with chemotherapy-induced thrombocytopenia. The agent led to high rates of platelet count correction and reduction in transfusion needs.
Skip Nav Destination
Gerald A. Soff, MD: Examining a New Indication for Romiplostim
December 30, 2021
Content License:Private